JOSE CLAUDIO MENEGHETTI

(Fonte: Lattes)
Índice h a partir de 2011
7
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Autor: MENEGHETTI, José Cláudio ×

Resultados de Busca

Agora exibindo 1 - 10 de 10
  • bookPart
  • article 6 Citação(ões) na Scopus
    A tomografia por emissão de pósitrons com 2-[18F]-fluoro-2-desoxi-D-glicose é custo-efetiva em pacientes com câncer de pulmão não pequenas células no Brasil
    (2012) CERCI, Juliano Julio; TAKAGAKI, Teresa Yae; TRINDADE, Evelinda; MORGADO, Roberta; MORABITO, Fausto; MUSOLINO, Rafael Silva; SOARES JUNIOR, José; MENEGHETTI, José Cláudio
    OBJECTIVE: To evaluate the accuracy and cost-effectiveness of metabolic staging (MS) with FDG-PET as compared with the conventional staging (CS) strategy in the preoperative staging of non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: A total of 95 patients with initial diagnosis of NSCLC were staged before undergoing treatment. The MS and CS results were compared with regard to treatment definition and incidence of futile thoracotomies with both strategies. RESULTS: Metabolic staging with FDG-PET upstaged 48.4% and downstaged 5.3% of the patients, and would lead to change in the treatment of 41% of cases. Thoracotomy was considered as futile in 47% of the patients with CS, and in 19% of the patients with MS. The cost of futile thoracotomies in eight patients with MS was R$ 79,720, while in 31 patients with CS it would be R$ 308,915. Just such saving in costs would be more than enough to cover the costs of all FDG-PETs (R$ 126,350) or FDG-PET/CTs (R$ 193,515) for the 95 patients. CONCLUSION: The metabolic staging with FDG-PET is more accurate than CS in patients with NSCLC. Both FDG-PET and FDG-PET/CT are cost-effective methods and their utilization is economically justifiable in the Brazilian public health system.
  • bookPart
    Inflamação e infecção cardiovasculares
    (2017) MENEGHETTI, José Cláudio; JúNIOR, José Soares; IZAKI, Marisa; GIORGI, Maria Clementina P.
  • bookPart
    O Papel Atual do Teste Ergométrico Associado a Métodos de Imagem na Avaliação do Risco
    (2018) CHALELA, William Azem; FALCãO, Andréa Marinho; MENEGHETTI, José Cláudio; TSUTSUI, Jeane
  • bookPart
    Cintilografia cardíaca com pirofosfato
    (2017) MENEGHETTI, José Cláudio; JúNIOR, José Soares; IZAKI, Marisa; GIORGI, Maria Clementina P.
  • bookPart
    Medicina Nuclear em Cardiologia
    (2016) MENEGHETTI, José Cláudio; BUCHPIGUEL, Carlos Alberto; SOARES JUNIOR, José; IZAKI, Marisa; GIORGI, Maria Clementina Pinto
  • bookPart
    Avaliação da função ventricular
    (2017) MENEGHETTI, José Cláudio; JúNIOR, José Soares; IZAKI, Marisa; GIORGI, Maria Clementina P.
  • bookPart
    Viabilidade miocárdica
    (2017) MENEGHETTI, José Cláudio; JúNIOR, José Soares; IZAKI, Marisa; GIORGI, Maria Clementina P.
  • bookPart
    Cintilografia de perfusão miocárdica
    (2017) MENEGHETTI, José Cláudio; JúNIOR, José Soares; IZAKI, Marisa; GIORGI, Maria Clementina P.; PADILHA, Bruno Gomes
  • article 4 Citação(ões) na Scopus
    Fluorodeoxyglucose-positron emission tomography staging can replace bone marrow biopsy in Hodgkin's lymphoma. Results from Brazilian Hodgkin's Lymphoma Study Group
    (2018) CERCI, Juliano Júlio; BOGONI, Mateos; BUCCHERI, Valeria; ETCHEBEHERE, Elba Cristina Sá de Camargo; SILVEIRA, Talita Maira Bueno da; BAIOCCHI, Otavio; PEREIRA NETO, Carlos de Araujo Cunha; SAPIENZA, Marcelo Tatit; MARIN, Jose Flavio Gomes; MENEGHETTI, José Cláudio; NOVIS, Yana; SOUZA, Carmino Antonio de; CHIATTONE, Carlos; TORRESAN, Marcia; RAMOS, Celso Dario
    ABSTRACT Objective: To investigate, in a large prospective multicenter study, whether 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography is sufficiently accurate to identify clinically important bone marrow involvement by Hodgkin's lymphoma to replace routine bone marrow biopsy in a developing tropical country. Methods: Patients newly diagnosed with Hodgkin's lymphoma were recruited from six cancer centers in Brazil. All were staged by the results of positron emission tomography/computed tomography that were centrally reviewed and by iliac crest bone marrow biopsy. Patients were classified as having marrow disease if they had lymphoma identified by marrow biopsy histology or had focal 2-[18F]-fluoro-2-deoxy-D-glucose marrow uptake that resolved following chemotherapy. Results: A total of 246 participants were recruited from six different centers and 62 (25.2%) were judged to have Hodgkin's lymphoma in the bone marrow. Positron emission tomography and biopsies were concordant in 206 patients (83%). Positron emission tomography correctly identified marrow disease in 59/62 patients (95.1%) and marrow biopsy in 25/62 patients (40.3%). In 22/62 (35.4%) patients, the two techniques were concordant in the diagnosis of marrow involvement. Of the forty discordant results, positron emission tomography found bone marrow involvement in 37 patients, upstaging 22 to stage IV and having an impact on therapeutic decision in nine cases given their reallocation from early to advanced stage. Three false negative positron emission tomography results were obtained with bone marrow biopsy giving positive findings. All three cases were classified as stage IV regardless of bone marrow findings implying no modification in the clinical management. The sensitivity, specificity and accuracy of positron emission tomography for detecting bone marrow disease were 95%, 100% and 98% and for bone marrow biopsy they were 40%, 100% and 84%, respectively. Conclusion: We conclude that positron emission tomography can replace marrow biopsy in Brazilian patients with Hodgkin's lymphoma without compromising clinical management.